Age (y) ±SD Fem/Mae MC n(%) No. Crisis ±SD ER n (%) No. ER ± SD PDM dose PDN use n (%) PDN dose mg ± SD AZA use n (%) AZA dose mg ± SD mg ± SD Comorbidity (n 252)                     Yes 185 (73%) 38 ± 18 63/37 64 (35) 1.8 ± 1.2 118 (64) 3.3 ± 3 360 ± 180 139 (75) 49 ± 26 87 (47) 77 ± 26 No 25 ± 9 91/9 20 (30) 1.3 ± 0.7 32 (48) 2 ± 2 328 ± 139 38 (57) 37 ± 18 19 (28) 68 ± 26 P <0.0001 <0.0001 NS NS 0.016 0.005 NS 0.004 0.011 0.006 NS OR 95% CI     1.2 (0.7-2.3)   1.92 (1.1-3.4)             Dyslipidemia (n 234)                     Yes  140 (60%) 39 ± 18 63/37 50 (36) 1.7 ± 1.2 94 (67) 3.4 ± 3.1 373 ± 182 106 (76) 49 ± 27 70 (50) 79 ± 27 No 31 ± 16 80/20 27 (29) 1.7 ± 1.2 45 (48) 2.8 ± 2.8 321 ± 148 60 (64) 42 ± 21 32 (34) 66 ± 24 P 0.001 0.004 NS NS 0.003 NS 0.023 0.035 NS 0.011 0.015 OR 95% CI     1.4 (0.8-2.4)   2.2 (1.3-3.8)             Dysthyroidism (n 233)                     Yes 45 (19%) 37 ± 17 76/24 15 (33) 2 ± 1.4 35 (78) 3.8 ± 3.1 374 ± 204 33 (73) 49 ± 31 20 (44) 73 ± 21 No 34 ± 17 70/30 61 (32) 1.6 ± 1 109 (58) 2.8 ± 2.8 348 ± 162 132 (70) 46 ± 24 82 (44) 76 ± 28 P NS NS NS NS 0.01 NS NS NS NS NS NS  OR 95% CI     1.0 (0.5-2.1)   2.5 (1.2-5.4)             Diabetes mellitus (n 252)                     Yes 50 (20%) 46 ± 17 56/44 24 (48) 1.7 ± 0.9 40 (80) 3.6 ± 3.6 410 ± 204 34 (68) 52 ± 21 27 (54) 82 ± 28 No 32 ± 16 74/26 60 (30) 1.7 ± 1.2 110 (55) 2.8 ± 2.6 337 ± 158 143 (71) 45 ± 26 79 (39) 73 ± 25 P <0.0001 0.012 0.012 NS 0.001 NS 0.006 NS 0.029 0.041 NS OR 95% CI     2.2 (1.2-4.1)   3.4 (1.6-7.1)             Hypertension (n 252)                     Yes 39 (15%) 54 ± 15 51/49 17 (44) 1.9 ± 1.2 31 (80) 3.4 ± 2.7 366 ± 203 33 (85) 48 ± 18 22 (56) 81 ± 31 No 31 ± 15 74/26 67 (31) 1.6 ± 1.1 119 (56) 2.9 ± 2.9 349 ± 164 144 (68) 46 ± 26 84 (39) 74 ± 25 P <0.0001 0.005 NS NS 0.004 NS NS 0.022 NS 0.037 NS OR 95% CI     1.7 (0.8-3.4)   3.1 (1.4-7)             Autoinmunedesease (n 253)                     Yes 17 (7%) 30 ± 12 94/6 2 (12) 1 ± 0 7 (41) 2.4 ± 2.6 367 ± 219 13 (77) 43 ± 14 6 (36) 92 ± 34 No 35 ± 17 69/31 82 (35) 1.7 ± 1.1 143 (61) 3.1 ± 2.9 351 ± 167 164 (70) 46 ± 26 100 (43) 74 ± 26 P NS 0.018 0.039 NS NS NS NS NS NS NS NS OR 95% CI     0.3 (0.1-1.1)   0.5 (0.2-1.2)             Thymoma (n 199)                     Yes 30 (15%) 44.5 ± 14 30/70 16 (53) 1.6 ± 0.7 21 (70) 2.9 ± 2.3 405 ± 253 27 (90) 48 ± 27 17 (57) 72 ± 23 No 29.5 ± 13 82/18 50 (30) 1.8 ± 1.3 95 (56) 3.3 ± 3.3 368 ± 154 115 (68) 46 ± 27 64 (38) 78 ± 28 P <0.0001 < 0.0001 0.011 NS NS NS NS 0.009 NS 0.043 NS OR 95% CI     2.7 (1.2-6)   1.8 (0.8-4.2)

Table 1: Prognosis of patients with Myasthenia gravis according to the presence or absence of comorbidities: Dyslipidemia, Thyroid disease, Diabetes, Hypertension, Autoimmune disease, Thymoma. AZA = Azathioprine, SD = Standard deviation, ER = Emergency Room visits, Fem= Female, Masc = Male, MC = Myasthenic crisis, No. = number, NS= Non significant, PDM = pyridostigmine, PDN = prednisone, OR= Odds ratio, CI = confidence interval